09:04 AM EDT, 10/03/2024 (MT Newswires) -- Teva Pharmaceutical Industries' ( TEVA ) subsidiary Teva Pharmaceuticals International has partnered with mAbxience to develop an anti-PD-1 oncology biosimilar, the companies said Thursday.

Under the agreement, mAbxience will handle development and production, while Teva will manage regulatory approvals and commercialization, the companies said.

Price: 17.50, Change: +0.04, Percent Change: +0.23